SCHEMBL17021218

SCHEMBL17021218

CC(C)C[C@H](NC(=O)C(Cc1ccccc1)NC(=O)c1cnccn1)B1OB([C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)c2cnccn2)OB([C@H](CC(C)C)NC(=O)[C@@H](Cc2ccccc2)NC(=O)c2cnccn2)O1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMB5 P28074 17/20 0.70
LONP1 P36776 11/20 0.70
PSMB8 P28062 10/20 0.70
PSMB9 P28065 10/20 0.70
PSMB6 P28072 10/20 0.70
PSMB10 P40306 10/20 0.70
PSMB11 A5LHX3 9/20 0.70
PSMA7 O14818 9/20 0.70
PSMB1 P20618 9/20 0.70
PSMA1 P25786 9/20 0.70
PSMA2 P25787 9/20 0.70
PSMA3 P25788 9/20 0.70
PSMA4 P25789 9/20 0.70
PSMA5 P28066 9/20 0.70
PSMB4 P28070 9/20 0.70
PSMB3 P49720 9/20 0.70
PSMB2 P49721 9/20 0.70
PSMA6 P60900 9/20 0.70
PSMA8 Q8TAA3 9/20 0.70
PSMB7 Q99436 9/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10071801 1.00 PSMB5 (0.70) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL10072156 1.00 PSMB5 (0.70) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL4419103 1.00 PSMB5 (0.70) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL24836934 0.96 PSMB5 (0.66) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL1688079 0.96 PSMB5 (0.66) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL1688078 0.95 PSMB5 (0.67) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL25598877 0.95 PSMB5 (0.64) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL10043059 0.94 PSMB5 (0.66) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL8091955 0.93 PSMB5 (0.62) PSMB5LONP1PSMB8PSMB9PSMB6
SCHEMBL25134755 0.92 PSMB5 (0.61) PSMB5LONP1PSMB8PSMB9PSMB6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9206229-B2 Bortezomib esters and formulations thereof CHEMI S.P.A. (IT) 2015-12-08 US disclosed
US-20150232508-A1 Bortezomib Esters And Formulations Thereof CHEMI S.P.A. a corporation 2015-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150232508-A1 Bortezomib Esters And Formulations Thereof TARBP2, TARDBP, TARBP1 PSMB5 64/4885LONP1 763/4885PSMB8 50/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.